Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world
After another dismal quarter for Novo Nordisk A/S shares, investors are looking to an experimental treatment of the most common form of dementia to help spark a revival.
The Danish drugmaker is scheduled to disclose results before the year is out from a pair of late-stage studies in patients with mild Alzheimer’s disease. The tests use a pill version of semaglutide — the key ingredient in the company’s hugely successful Ozempic diabetes and Wegovy weight-loss shots.